TBPH Stock - Theravance Biopharma, Inc.
Unlock GoAI Insights for TBPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $64.38M | $57.42M | $51.35M | $55.31M | $71.86M |
| Gross Profit | $64.38M | $16.80M | $-12,046,000 | $-138,346,000 | $71.86M |
| Gross Margin | 100.0% | 29.3% | -23.5% | -250.1% | 100.0% |
| Operating Income | $-46,949,000 | $-56,035,000 | $-91,957,000 | $-257,784,000 | $-297,627,000 |
| Net Income | $-56,418,000 | $-55,193,000 | $872.13M | $-199,426,000 | $-278,017,000 |
| Net Margin | -87.6% | -96.1% | 1698.5% | -360.6% | -386.9% |
| EPS | $-1.15 | $-1.00 | $-1.26 | $-2.87 | $-4.46 |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Oppenheimer | Initiation | Outperform | $27 |
| September 12th 2025 | B. Riley Securities | Initiation | Buy | $28 |
| August 6th 2024 | Leerink Partners | Downgrade | Market Perform | $10← $15 |
| April 12th 2024 | BTIG Research | Initiation | Buy | $21 |
| January 8th 2024 | Evercore ISI | Downgrade | In-line | - |
| May 23rd 2022 | SVB Leerink | Initiation | Outperform | $12 |
Earnings History & Surprises
TBPHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.46 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.03 | $0.04 | +233.3% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.14 | $-0.08 | +42.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.11 | $-0.17 | -54.5% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.09 | $-0.13 | -44.4% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.19 | $-0.09 | +52.6% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $0.04 | $0.03 | -14.4% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.10 | $-0.01 | +90.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.12 | $-0.24 | -100.0% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.30 | $-0.43 | -43.3% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.60 | $-0.48 | +20.0% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.96 | $-0.80 | +16.7% | ✓ BEAT |
Latest News
Oppenheimer Initiates Coverage On Theravance Biopharma with Outperform Rating, Announces Price Target of $27
📈 PositiveBTIG Maintains Buy on Theravance Biopharma, Raises Price Target to $40
📈 PositiveHC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $20
📈 PositiveTheravance Biopharma Q3 EPS $0.07 Beats $(0.13) Estimate, Sales $19.990M Beat $19.960M Estimate
📈 PositiveTheravance Biopharma To Present Ampreloxetine nOH/MSA Data In Four Presentations At 36th AAS Autonomic Symposium (Nov. 5–8, Clearwater Beach, FL); Phase 3 CYPRESS Topline Due Q1 2026
📈 PositiveTheravance Biopharma Will Be Presenting At CHEST 2025, The Annual Meeting Of The American College Of Chest Physicians
➖ NeutralB. Riley Securities Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $28
📈 PositiveTheravance Biopharma Completes Enrollment In Pivotal Phase 3 Trial For Blood Pressure Disorder, Advances Phase 3 CYPRESS Study Targeting Rare Neurodegenerative Disease Affecting MSA Patients
📈 PositiveTheravance and Mylan Entered Settlement Agreement With Cipla Over YUPELRI (Revefenacin) Inhalation Solution
➖ NeutralTheravance Sales Jump 83 Percent
📈 PositiveTheravance higher as China approves Viatris-partnered COPD therapy
📈 PositiveFrequently Asked Questions about TBPH
What is TBPH's current stock price?
What is the analyst price target for TBPH?
What sector is Theravance Biopharma, Inc. in?
What is TBPH's market cap?
Does TBPH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TBPH for comparison